Trials / Completed
CompletedNCT00479570
Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.
Phase 2A Multi-Centre, Double Blind, Placebo Controlled 3-Way Cross-Over Study To Investigate The Effect Of Single Doses Of PF-00446687 On Sexual Arousal And Sexual Desire In Women Suffering From Female Sexual Dysfunction (FSD).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 45 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effect of up to 200 mg of PF-00446687 on acute sexual arousal and sexual interest in post menopausal females, as well as examining the safety and toleration of the drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-00446687 | Single 200mg dose |
| DRUG | Placebo |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2007-05-28
- Last updated
- 2019-01-31
Locations
3 sites across 3 countries: Denmark, Norway, Sweden
Source: ClinicalTrials.gov record NCT00479570. Inclusion in this directory is not an endorsement.